SI3197898T1 - Nove spojine imidazopiridazina in njihova uporaba - Google Patents

Nove spojine imidazopiridazina in njihova uporaba

Info

Publication number
SI3197898T1
SI3197898T1 SI201531035T SI201531035T SI3197898T1 SI 3197898 T1 SI3197898 T1 SI 3197898T1 SI 201531035 T SI201531035 T SI 201531035T SI 201531035 T SI201531035 T SI 201531035T SI 3197898 T1 SI3197898 T1 SI 3197898T1
Authority
SI
Slovenia
Prior art keywords
imidazopyridazine compounds
novel
novel imidazopyridazine
compounds
imidazopyridazine
Prior art date
Application number
SI201531035T
Other languages
English (en)
Inventor
Wei-Guo Su
Guangxiu Dai
Weihan Zhang
Wei Deng
Original Assignee
Hutchison Medipharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Limited filed Critical Hutchison Medipharma Limited
Publication of SI3197898T1 publication Critical patent/SI3197898T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
SI201531035T 2014-09-24 2015-09-23 Nove spojine imidazopiridazina in njihova uporaba SI3197898T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410494483.5A CN105503877A (zh) 2014-09-24 2014-09-24 咪唑并哒嗪类化合物及其用途
PCT/CN2015/090367 WO2016045591A1 (en) 2014-09-24 2015-09-23 Novel imidazopyridazine compounds and their use
EP15843649.3A EP3197898B1 (en) 2014-09-24 2015-09-23 Novel imidazopyridazine compounds and their use

Publications (1)

Publication Number Publication Date
SI3197898T1 true SI3197898T1 (sl) 2020-03-31

Family

ID=55580324

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531035T SI3197898T1 (sl) 2014-09-24 2015-09-23 Nove spojine imidazopiridazina in njihova uporaba

Country Status (32)

Country Link
US (2) US10208066B2 (sl)
EP (1) EP3197898B1 (sl)
JP (1) JP6381792B2 (sl)
KR (2) KR102111570B1 (sl)
CN (2) CN105503877A (sl)
AR (1) AR101964A1 (sl)
AU (1) AU2015320142B2 (sl)
BR (1) BR112017006002B1 (sl)
CA (1) CA2958671C (sl)
CL (1) CL2017000682A1 (sl)
CY (1) CY1122763T1 (sl)
DK (1) DK3197898T3 (sl)
EA (1) EA032643B1 (sl)
ES (1) ES2765510T3 (sl)
HR (1) HRP20192279T1 (sl)
HU (1) HUE047377T2 (sl)
IL (1) IL250703B (sl)
LT (1) LT3197898T (sl)
MX (1) MX2017003902A (sl)
MY (1) MY178136A (sl)
NZ (1) NZ729886A (sl)
PE (1) PE20170936A1 (sl)
PH (1) PH12017500564B1 (sl)
PL (1) PL3197898T3 (sl)
PT (1) PT3197898T (sl)
RS (1) RS59831B1 (sl)
SG (1) SG11201701545YA (sl)
SI (1) SI3197898T1 (sl)
TW (1) TWI707855B (sl)
UA (1) UA118066C2 (sl)
WO (1) WO2016045591A1 (sl)
ZA (1) ZA201701312B (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105503877A (zh) * 2014-09-24 2016-04-20 和记黄埔医药（上海）有限公司 咪唑并哒嗪类化合物及其用途
CN109516973A (zh) * 2017-09-19 2019-03-26 南京圣和药业股份有限公司 取代嘧啶类化合物、其制备方法及用途
CN110386937A (zh) * 2018-04-20 2019-10-29 和记黄埔医药（上海）有限公司 化合物的晶型和无定型
AR117461A1 (es) 2018-12-20 2021-08-04 Bayer Ag Compuestos de heterociclil piridazina como fungicidas
CN110028502B (zh) * 2019-05-29 2020-02-14 济南周行医药科技有限公司 一种激酶抑制剂类药物中间体的制备方法
US20240016152A1 (en) 2020-06-18 2024-01-18 Bayer Aktiengesellschaft Active compound combinations
CN114031558A (zh) * 2021-12-14 2022-02-11 无锡捷化医药科技有限公司 一种1-(6-氯哒嗪-4-基）乙基-1-酮的制备方法
WO2023143496A1 (zh) * 2022-01-28 2023-08-03 和记黄埔医药（上海）有限公司 咪唑并[1,2-b]哒嗪类化合物的中间体的合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773958A (en) 1997-01-03 1998-06-30 Ovonic Battery Company, Inc. Apparatus for detecting cell reversal in rechargeable batteries
KR100389192B1 (ko) 1997-04-25 2003-06-27 다케다 야쿠힌 고교 가부시키가이샤 축합 피리다진 유도체, 그것의 제조 방법 및 용도
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
US8097617B2 (en) 2006-03-31 2012-01-17 Novartis Ag Organic compounds
MX2009004623A (es) 2006-10-30 2009-05-15 Novartis Ag Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
EP2089393A1 (en) 2006-10-30 2009-08-19 Novartis AG Heterocyclic compounds as antiinflammatory agents
CN101528748A (zh) * 2006-10-30 2009-09-09 诺瓦提斯公司 作为pi3k脂质激酶抑制剂的咪唑并哒嗪类化合物
AU2008250328A1 (en) 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as PI3K lipid kinase inhibitors
EP2217601A1 (en) * 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
WO2009085230A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
NZ592880A (en) 2008-11-13 2013-06-28 Gilead Calistoga Llc Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy
WO2012116237A2 (en) * 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US20140235643A1 (en) * 2011-10-04 2014-08-21 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
US20130143902A1 (en) 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
WO2013090725A1 (en) 2011-12-15 2013-06-20 Philadelphia Health & Education Corporation NOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
ES2685568T3 (es) 2012-12-21 2018-10-10 Gilead Calistoga Llc Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa
CN105503877A (zh) * 2014-09-24 2016-04-20 和记黄埔医药（上海）有限公司 咪唑并哒嗪类化合物及其用途

Also Published As

Publication number Publication date
MX2017003902A (es) 2017-12-07
AU2015320142A1 (en) 2017-04-27
TWI707855B (zh) 2020-10-21
PT3197898T (pt) 2020-01-17
US20170253618A1 (en) 2017-09-07
CA2958671A1 (en) 2016-03-31
AU2015320142B2 (en) 2018-02-15
KR102006670B1 (ko) 2019-10-01
WO2016045591A1 (en) 2016-03-31
EP3197898A4 (en) 2018-03-14
CN106715432B (zh) 2019-03-26
IL250703A0 (en) 2017-04-30
PE20170936A1 (es) 2017-07-13
KR102111570B1 (ko) 2020-05-18
CY1122763T1 (el) 2021-03-12
KR20170048598A (ko) 2017-05-08
IL250703B (en) 2020-09-30
CN105503877A (zh) 2016-04-20
RS59831B1 (sr) 2020-02-28
NZ729886A (en) 2020-06-26
TW201612181A (en) 2016-04-01
HRP20192279T1 (hr) 2020-03-06
JP6381792B2 (ja) 2018-08-29
US10611777B2 (en) 2020-04-07
JP2017528500A (ja) 2017-09-28
KR20190090065A (ko) 2019-07-31
PH12017500564A1 (en) 2017-08-30
EP3197898A1 (en) 2017-08-02
EA032643B1 (ru) 2019-06-28
AR101964A1 (es) 2017-01-25
UA118066C2 (uk) 2018-11-12
MY178136A (en) 2020-10-05
US10208066B2 (en) 2019-02-19
CL2017000682A1 (es) 2017-10-30
PL3197898T3 (pl) 2020-06-29
BR112017006002B1 (pt) 2023-02-14
SG11201701545YA (en) 2017-04-27
EP3197898B1 (en) 2019-11-27
PH12017500564B1 (en) 2017-08-30
BR112017006002A2 (pt) 2017-12-19
LT3197898T (lt) 2020-02-10
HUE047377T2 (hu) 2020-04-28
ZA201701312B (en) 2019-06-26
CA2958671C (en) 2019-04-30
ES2765510T3 (es) 2020-06-09
DK3197898T3 (da) 2020-01-20
CN106715432A (zh) 2017-05-24
US20190127391A1 (en) 2019-05-02
EA201790276A1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
IL252135B (en) Triazolopyrimidine compounds and their uses
IL266108A (en) imidazopyridazines
GB201401617D0 (en) Novel combination and use
ZA201701312B (en) Novel imidazopyridazine compounds and their use
HK1243950A1 (zh) 新型組合物和用途
HK1243077A1 (zh) 呱啶基吡唑並嘧啶酮及其用途
GB201416727D0 (en) Use
GB201416716D0 (en) Use
GB201613134D0 (en) Novel compounds and their use
GB201513318D0 (en) Novel compounds and their use
GB201413411D0 (en) Novel compounds and their use
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201514770D0 (en) Compounds and their use
GB201421960D0 (en) Use
GB201420535D0 (en) Use
GB201420534D0 (en) Use
GB201420365D0 (en) Use
GB201404301D0 (en) Compounds and combinations
GB201402467D0 (en) New Compounds and uses